Filing

                                                                    EXHIBIT 99.1

                ADVENTRX COMPLETES $20 MILLION PRIVATE PLACEMENT
                       WITH CARL ICAHN AS LARGEST INVESTOR

SAN DIEGO - AUGUST 1, 2005 - ADVENTRX Pharmaceuticals, Inc. (Amex: ANX) today
announced that it has closed its previously announced $20 million private
placement of common stock and warrants. Investment funds controlled by Carl
Icahn were the largest investors in the transaction, together with Viking Global
Investors LP. Icahn investors and Viking will have the right to designate one
director to the ADVENTRX Board of Directors.

"With this financing now closed we intend to continue to focus on the
development of our lead product, CoFactor(TM), to broaden our product pipeline
and to execute on our strategy to introduce improved anticancer and antiviral
treatments," said Evan M. Levine, president and CEO for ADVENTRX.

The private placement consisted of the sale of 10,810,809 shares of the
Company's common stock, as well as the issuance of warrants to purchase
10,810,809 shares of common stock at an exercise price of $2.26 per share. CIBC
World Markets acted as the lead placement agent and RBC Capital Markets acted as
the co-placement agent for this transaction.

Additional information regarding this transaction is available through the
Company's filing on Form 8-K with the Securities and Exchange Commission.

ABOUT ADVENTRX
ADVENTRX Pharmaceuticals is a biopharmaceutical research and development company
focused on introducing new technologies for anticancer and antiviral treatments
that improve the performance and safety of existing drugs, by addressing
significant problems such as drug metabolism, toxicity, bioavailability or
resistance. The Company's lead compound, CoFactor, is a biomodulator of
5-fluorouracil (5-FU), a widely used cancer chemotherapy. CoFactor is currently
being tested with 5-FU in a US-based Phase II and an EU-based Phase IIb clinical
trial as a first line treatment of metastatic colorectal cancer. In addition,
CoFactor has received clearance under a special protocol assessment from the US
FDA to begin a Phase III pivotal clinical trial for metastatic colorectal
cancer. More information can be found on the Company's Web site at
www.adventrx.com.

Forward Looking Statement
This press release contains forward-looking statements within the meaning of the
"safe harbor" provisions of the Private Securities Litigation Reform Act of
1995. Such statements are made based on management's current expectations and
beliefs. Actual results may vary from those currently anticipated based upon a
number of factors, including uncertainties inherent in the drug development
process, the timing and success of clinical trials, the validity of research
results, and the receipt of necessary approvals from the FDA and other
regulatory agencies. For a discussion of such risks and uncertainties, which
could cause actual results to differ from those contained in the forward-looking
statements, see "Risk Factors" in the Company's last quarterly report on Form
10-Q, as well as other reports that the Company files from time to time with the
Securities and Exchange Commission. All forward-looking statements are qualified
in their entirety by this cautionary statement. The Company undertakes no
obligation to release publicly any revisions, which may be made to reflect
events or circumstances after the date hereof.


Contact:
ADVENTRX PHARMACEUTICALS
Andrea Lynn
858-552-0866

Investor Contact:
LIPPERT HEILSHORN & ASSOCIATES
Jody Cain (jcain@lhai.com)
Brandi Floberg (bfloberg@lhai.com)
310-691-7100



                                      # # #

                                                                    EXHIBIT 99.2

ADVENTRX PRESENTS POSITIVE THIOVIR DATA AT IAS 2005 CONFERENCE

SAN DIEGO - JULY 26, 2005 - ADVENTRX Pharmaceuticals, Inc. (Amex: ANX) today
announced data from an in vitro study indicating that Thiovir(TM), the Company's
non-nucleoside reverse transcriptase inhibitor (NNRTI), demonstrated
effectiveness against human immunodeficiency virus type-1 (HIV-1), which is
resistant to other NNRTIs and nucleoside reverse transcriptase inhibitors
(NRTIs). Thiovir also exhibited a slightly higher level of antiviral activity
against HIV-1 than foscarnet, a currently marketed, broad spectrum antiviral
indicated for treatment of opportunistic infections in HIV patients. A poster of
the study data was presented at the 3rd International AIDS Society Conference
(IAS 2005) on HIV Pathogenesis and Treatment in Rio de Janeiro.

"Due to its oral delivery, higher antiviral activity and greater antiviral
activity against drug resistant virus, Thiovir continues to show promise as an
alternative to foscarnet, which is an effective antiviral, but has limited use
due to its toxicity and inconvenient delivery by protracted intravenous
administration," said Joan M. Robbins, Ph.D., ADVENTRX chief technical officer
and co-author of the study.

"In combination testing with zidovudine, an NRTI, Thiovir was highly
synergistic, while foscarnet was only slightly synergistic to antagonistic. This
has important clinical implications as suitable drug regimens combining Thiovir
with an NRTI could allow for decreased drug dosage," added Dr. Robbins.

The poster "Anti-HIV-1 Activity of a Foscarnet Analogue, Synergy with Zidovudine
and Analysis of Resistance Variants Selected in Vitro" was presented by ADVENTRX
senior scientist Shani Waninger, Ph.D. Copies of the poster are available on the
"Resource Library" section of the Company's Web site at www.adventrx.com.

ABOUT THIOVIR
Thiovir is a non-nucleoside reverse transcriptase inhibitor (NNRTI) designed for
oral delivery as a component of AZT-based highly active antiretroviral therapy
(HAART). Thiovir is a prodrug for foscarnet that delivers both the active drug
TPFA (thiophosphonoformate) and the active metabolite PFA (foscarnet) in an oral
formulation. Thiovir is intended to deliver all of the benefits of the
FDA-approved drug foscarnet, including broad spectrum antiviral activity, with
the added benefit of improved cell permeability. ADVENTRX currently plans to
file an investigational new drug application with the US Food and Drug
Administration in the first quarter of 2006.

ABOUT ADVENTRX
ADVENTRX Pharmaceuticals is a biopharmaceutical research and development company
focused on introducing new technologies for anticancer and antiviral treatments
that improve the performance and safety of existing drugs, by addressing
significant problems such as drug metabolism, toxicity, bioavailability or
resistance. The Company's lead compound, CoFactor(TM), is a biomodulator of
5-fluorouracil (5-FU), a widely used cancer chemotherapy. CoFactor is currently
being tested with 5-FU in a US-based Phase II and an EU-based Phase IIb clinical
trial as a first line treatment of metastatic colorectal cancer. In addition,
CoFactor has received clearance under a special protocol assessment from the US
Food and Drug Administration to begin a Phase III pivotal clinical trial for
metastatic colorectal cancer. More information can be found on the Company's Web
site at www.adventrx.com.

FORWARD LOOKING STATEMENT
This press release contains forward-looking statements within the meaning of the
"safe harbor" provisions of the Private Securities Litigation Reform Act of
1995. Such statements are made based on management's current expectations and
beliefs. Actual results may vary from those currently anticipated based upon a
number of factors, including uncertainties inherent in the drug development
process, the timing and success of clinical trials, the validity of research
results, and the receipt of necessary approvals from the U.S. Food and Drug
Administration (FDA) and other regulatory agencies. For a discussion of such
risks and uncertainties, which could cause actual results to differ from those
contained in the forward-looking statements, see "Risk Factors" in the Company's
last quarterly report on Form 10-Q, as well as other reports that the Company
files from time to time with the Securities and Exchange Commission. All
forward-looking statements are qualified in their entirety by this cautionary
statement. The Company undertakes no obligation to release publicly any
revisions, which may be made to reflect events or circumstances after the date
hereof.

CONTACT:
ADVENTRX PHARMACEUTICALS
Andrea Lynn
858-552-0866

INVESTOR CONTACT:
LIPPERT HEILSHORN & ASSOCIATES
Jody Cain (jcain@lhai.com)
Brandi Floberg (bfloberg@lhai.com)
310-691-7100

                                       ###